MacroGenics MGC026 Phase 1 meets SCCHN Stage 1 threshold; ESMO poster accepted

MACROGENICS INC

MGC026, a B7-H3-directed ADC, achieved pre-specified Stage 1 response threshold in SCCHN cohort; Stage 2 enrollment underway.
Dose escalation completed; 7.5 mg/kg q3W selected for expansion in SCCHN, endometrial, melanoma, soft tissue sarcoma.
As of July 8, 2026, 74 patients enrolled; no interstitial lung disease or ocular toxicity reported.
Interim Phase 1 results accepted for poster at ESMO 2026 (Oct 23-27, Madrid); also lorigerlimab poster on gynecologic cancers.
CEO Eric Risser: 'look forward to sharing data at ESMO.'

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.